CTN 244: STOP HIV & AIDS in IDU
Seek and Treat for Optimal outcomes and Prevention in HIV & AIDS in IDU
About The Study
This study expanded antiretroviral therapy (ART) coverage among injection drug users (IDUs) in the Downtown East Side of Vancouver, BC. From 2010 to 2016, researchers studied if expanded ART among IDUs led to a reduction in the number of new HIV infections and a decrease in adverse HIV/AIDS health outcomes among the target population.
The study enrolled adults living with HIV who inject drugs who are medically eligible for ART (based on current guidelines), but are not accessing therapy or are unaware of their HIV infection status.
Background
We know that ART can directly prevent HIV transmission by rendering the virus undetectable and significantly decreasing the risk of transmission. This was a novel approach to reducing new HIV infections when this study was launched. Knowledge gained from this study assisted in the development of a public health policy for the expansion of ART, as well as to enhance the effectiveness of traditional prevention efforts aimed to reduce HIV incidence.
Results
As hypothesized, expansion of ART resulted in substantial improvements in the proportions of people diagnosed, on ART, and virologically suppressed. Changes in the types of ART available resulted in a decrease in drug interactions and non-recommended drug combinations. People in this cohort were frequently co-prescribed opioids and benzodiazepines. This research provides valuable information, both locally and in other jurisdictions, about the benefits of expanding ART access, the complex medical needs of some people living with HIV, and the cascade of care.
Background
We know that ART can directly prevent HIV transmission by rendering the virus undetectable and significantly decreasing the risk of transmission. This was a novel approach to reducing new HIV infections when this study was launched. Knowledge gained from this study assisted in the development of a public health policy for the expansion of ART, as well as to enhance the effectiveness of traditional prevention efforts aimed to reduce HIV incidence.
Vel et tristique magna quam. Amet vel ac non nunc. Ut enim, amet, vestibulum lorem id enim elit, feugiat facilisis. Posuere erat eu ut consequat nunc. Amet egestas donec eros amet ultricies mi aliquam. Non eget semper mollis enim scelerisque malesuada eget. Porttitor pretium nibh nibh vitae convallis. Diam at et consequat viverra felis, purus. Et odio mollis facilisis proin cras ullamcorper integer tortor. Sit tincidunt viverra turpis aliquet enim. Quam neque nibh rhoncus tortor. Neque sed dolor aliquet sagittis, malesuada.
Study Approach
Viverra varius diam risus urna quam vivamus. Tempor lorem neque, orci eget tincidunt condimentum fringilla. Et convallis et magna enim nullam magna sit dictum iaculis. Malesuada potenti faucibus lacus placerat pulvinar augue tempus placerat bibendum. Blandit felis nunc porta enim lectus sem. Sed at habitant convallis facilisis viverra. Non volutpat, elementum nisi phasellus pharetra fusce.
Vel et tristique magna quam. Amet vel ac non nunc. Ut enim, amet, vestibulum lorem id enim elit, feugiat facilisis. Posuere erat eu ut consequat nunc. Amet egestas donec eros amet ultricies mi aliquam. Non eget semper mollis enim scelerisque malesuada eget. Porttitor pretium nibh nibh vitae convallis. Diam at et consequat viverra felis, purus. Et odio mollis facilisis proin cras ullamcorper integer tortor. Sit tincidunt viverra turpis aliquet enim. Quam neque nibh rhoncus tortor. Neque sed dolor aliquet sagittis, malesuada.
Investigators
Here’s who is leading this study.
Can’t find what you’re looking for?
Email ctninfo@ctnplus.ca.
Related Studies
-
CTN 248: Incentives to Stop AIDS and HIV in Drug Users
A randomized clinical trial evaluating the role of contingent reinforcement in the engagement and retention of Drug Users in HAART programs: a substudy of CTN 244

